Search

Your search keyword '"Marmont, F."' showing total 198 results
Start Over Author "Marmont, F."
198 results on '"Marmont, F."'

2. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia

Author

Pich, A., Riera, L., Sismondi, F., Godio, L., Bonino, L. Davico, Marmont, F., and di Celle, P. Francia

Subjects
Gene mutations -- Research, Gene mutations -- Physiological aspects, Leukemia -- Research, Leukemia -- Genetic aspects, Myeloproliferative disorders -- Research, Myeloproliferative disorders -- Genetic aspects, Health, World Health Organization -- Standards
Published
2009

7. PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C, Spinelli, O, Salmoiraghi, S, Intermesoli, T, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Elidi, L, Delaini, F, Oldani, E, Gianfaldoni, G, Bosi, A, Marmont, F, Audisio, E, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Falini, B, Pavoni, C, Bassan, R, Rambaldi, A, and Lussana, F

Published
2019

10. MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)

Author

Spinelli, O, Salmoiraghi, S, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Zannino, L, Intermesoli, T, Lussana, F, Delaini, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Marmont, F, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Audisio, E, Bosi, A, Falini, B, Pavoni, C, Bassan, R, and Rambaldi, A

Published
2018

11. PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C., primary, Spinelli, O., additional, Salmoiraghi, S., additional, Intermesoli, T., additional, Zanghì, P., additional, Cavagna, R., additional, Michelato, A., additional, Buklijas, K., additional, Elidi, L., additional, Delaini, F., additional, Oldani, E., additional, Gianfaldoni, G., additional, Bosi, A., additional, Marmont, F., additional, Audisio, E., additional, Ferrero, D., additional, Terruzzi, E., additional, De Paoli, L., additional, Rossi, G., additional, Borlenghi, E., additional, Cavattoni, I., additional, Tajana, M., additional, Scattolin, A.M., additional, Mattei, D., additional, Corradini, P., additional, Campiotti, L., additional, Ciceri, F., additional, Bernardi, M., additional, Todisco, E., additional, Cortelezzi, A., additional, Cortelazzo, S., additional, Falini, B., additional, Pavoni, C., additional, Bassan, R., additional, Rambaldi, A., additional, and Lussana, F., additional

Published
2019
Full Text
View/download PDF

14. NEXT GENERATION SEQUENCING (NGS) CONFIRMED THE ADVERSE CLINICAL IMPACT OF RUNX1 MUTATIONS IN A SUBSET OF ACUTE MYELOID LEUKEMIA NORMAL KARYOTYPE PATIENTS NEGATIVE FOR RISK DEFINING GENES MUTATIONS AND HOMOGENOUSLY TREATED WITHIN A CLINICAL TRIAL (NILG AML 02/06)

Author

Salmoiraghi, S, Zanghi, P, Pavoni, C, Montalvo, Mlg, Ubiali, G, Intermesoli, T, Oldani, E, Marmont, F, Cavattoni, I, Mattei, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Ciceri, F, Campiotti, L, Corradini, P, Cortelezzi, A, Ferrero, D, Audisio, E, Bosi, A, Bassan, R, Rambaldi, A, and Spinelli, O

Published
2017

15. TWO-STEP RESPONSE-ORIENTED INDUCTION PREDICTS LONG-TERM OUTCOME OF ADULT PATIENTS WITH STANDARD- AND HIGH-RISK ACUTE MYELOID LEUKAEMIA (AML): A NORTHERN ITALY LEUKAEMIA GROUP (NILG) STUDY

Author

Intermesoli, T, Oldani, E, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, F, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Fumagalli, M, Audisio, E, Fabris, P, Chisesi, T, Spinelli, O, Tosi, M, Giussani, U, Barbui, T, Rambaldi, A, Bassan, R, Intermesoli, T, Oldani, E, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, Fabio, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Fumagalli, M, Audisio, E, Fabris, P, Chisesi, T, Spinelli, O, Tosi, M, Giussani, U, Barbui, T, Rambaldi, A, and Bassan, R.

Published
2010

16. IN ADULT ACUTE MYELOID LEUKAEMIA (AML) ALL RISK SUBSETS BENEFIT FROM A SEQUENTIAL HIGH-DOSE PROGRAMME AS EARLY RESCUE OF FIRST INDUCTION FAILURE: A REPORT FROM NORTHERN ITALY LEUKAEMIA GROUP (NILG)

Author

Intermesoli, T, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, F, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Verga, L, Audisio, E, Fabris, P, Chisesi, T, Giussani, U, Spinelli, O, Zanghi, P, Oldani, E, Barbui, T, Rambaldi, A, Bassan, R, Intermesoli, T, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, Fabio, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Verga, L, Audisio, E, Fabris, P, Chisesi, T, Giussani, U, Spinelli, O, Zanghi, P, Oldani, E, Barbui, T, Rambaldi, A, and Bassan, R.

Published
2010

22. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis

Author

Busca, A., Cavecchia, I., Locatelli, F., D'Ardia, S., DE ROSA, Francesco Giuseppe, Marmont, F., Ciccone, G., Baldi, I., Serra, R., Gaido, E., and Falda, M.

Subjects
Adult, Male, Ofloxacin, Adolescent, Incidence, Hematopoietic Stem Cell Transplantation, Candidemia, Bacteremia, Levofloxacin, Antibiotic Prophylaxis, Middle Aged, Gram-Positive Bacteria, Anti-Bacterial Agents, Young Adult, Candida albicans, Drug Resistance, Bacterial, Gram-Negative Bacteria, Humans, Transplantation, Homologous, Female, Aged, Candida, Fluoroquinolones
Abstract

Blood stream infections (BSIs) remain one of the major causes of morbidity and mortality for patients receiving an allogeneic hematopoietic stem cell transplantation (HSCT). In the present study, we evaluated the incidence and characteristics of BSI within 1 year after allogeneic HSCT in 269 consecutive adult patients who received antibacterial prophylaxis with levofloxacin. Cumulative incidence of BSI was 12% (95% confidence interval, 8-16%). Bacteria were responsible for 30 out of the 32 BSI, while fungi were responsible for 2 episodes of BSI. The median onset of BSI was day 8 (range 1-328 days) post transplant, and 66% of BSI occurred before neutrophil recovery. Gram-positive organisms accounted for 60% (n=18) of bacteremia, and gram-negative isolates for 40% (n=12) of the cases. Coagulase-negative staphylococci were the most commonly isolated gram-positive pathogens (53% of the cases), while Escherichia coli was the most commonly isolated gram-negative bacteria (58% of the cases). Candida albicans and Candida guillermondii were isolated from patients with candidemia. Resistance to fluoroquinolones (FQ) was common with 13% of gram-positive isolates being susceptible to FQ, while 50% of the gram-negative rods were susceptible to FQ. Crude mortality and mortality attributable to BSI were both 3% (1 of 32). In conclusion, our data suggest that despite the emergence of antibiotic resistance, FQ prophylaxis may be considered an appealing approach in allogeneic HSCT recipients and is also worth evaluating in randomized studies.

Published
2011

24. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

Author

Avvisati, G, Lo Coco, F, Paoloni, Fp, Petti, Mc, Diverio, D, Vignetti, M, Latagliata, R, Specchia, G, Baccarani, M, Di Bona, E, Fioritoni, G, Marmont, F, Rambaldi, A, DI RAIMONDO, Francesco, Kropp, Mg, Pizzolo, G, Pogliani, Em, Rossi, G, Cantore, N, Nobile, F, Gabbas, A, Ferrara, F, Fazi, P, Amadori, S, Mandelli, F, Gimema, Aieop, and EORTC Cooperative Groups

Published
2011

26. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia

Author

Bassan, R., primary, Masciulli, A., additional, Intermesoli, T., additional, Audisio, E., additional, Rossi, G., additional, Pogliani, E. M., additional, Cassibba, V., additional, Mattei, D., additional, Romani, C., additional, Cortelezzi, A., additional, Corti, C., additional, Scattolin, A. M., additional, Spinelli, O., additional, Tosi, M., additional, Parolini, M., additional, Marmont, F., additional, Borlenghi, E., additional, Fumagalli, M., additional, Cortelazzo, S., additional, Gallamini, A., additional, Marfisi, R. M., additional, Oldani, E., additional, and Rambaldi, A., additional

Published
2015
Full Text
View/download PDF

31. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia

Author

Chiusa, L., Di Celle, P. F., Campisi, P., Ceretto, C., Marmont, F., and achille PICH

Subjects
Adult, Male, adult acute lymphoblastic leukemia, quantitative WT1 expression, prognosis, Adolescent, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Predictive Value of Tests, Humans, Female, RNA, Messenger, WT1 Proteins, Aged
Abstract

We quantified Wilm's tumor gene (WT1) using a real time quantitative polymerase chain reaction in 20 adult patients with acute lymphoblastic leukemia at presentation. A WT1 level greater than 906 (median value for the whole series) was a significant predictor of a poor disease-free and overall survival in uni- and multivariate analyses.

Published
2006

33. BREAST CANCER RESISTANCE PROTEIN (BCRP) EXPRESSION AFFECT EVENT-FREE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Author

Gregorj, C, DE CAVE, Fabiana, Petrucci, Mt, Ricciardi, Maria Rosaria, Scerpa, Mc, Vignetti, M, Vitale, A, Meloni, G, Liso, V, Di Raimondo, F, Ferrara, F, Fabbiano, F, Camera, A, Fioritoni, G, Miraglia, E, Annino, L, Cascavilla, N, Marmont, F, Mazza, P, Perbellini, O, Cartore, N, Luppi, M, Nobile, F, Sica, S, Salvi, F, Mandelli, Franco, Foà, R., and Tafuri, Agostino

Published
2006

35. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy

Author

Breccia, M, Diverio, D, Noguera, Ni, Visani, G, Santoro, A, Locatelli, F, Damiani, Daniela, Marmont, F, Vignetti, M, Petti, Mc, and Lo Coco, F.

Subjects
Adult, Male, Neoplasm, Residual, Oncogene Proteins, Fusion, Adolescent, Tretinoin, Acute, Polymerase Chain Reaction, methods, drug therapy/genetics, Leukemia, Promyelocytic, Acute, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, genetics, Child, Preschool, Fusion, Tumor Markers, Aged, Promyelocytic, Oncogene Proteins, diagnostic use/genetics, Leukemia, Remission Induction, DNA, Neoplasm, DNA, Middle Aged, Biological, therapeutic use, Neoplasm, Female, Idarubicin, Molecular Diagnostic Techniques, Neoplasm Proteins, Residual, Treatment Outcome, Child, Preschool, Settore MED/15 - Malattie del Sangue
Abstract

Front line treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) and chemotherapy (CHT) results in molecular remission in approximately 95% of patients tested after consolidation. The small fraction of patients with persistence of molecular disease (i.e. those in whom polymerase chain reaction (PCR) is positive for PML/RARalpha) after such therapy are thought to have a dismal prognosis but has not yet been investigated in detail.We analyzed the clinico-biological features at presentation of APL patients who showed PCR-detectable residual disease and compared them to those of patients achieving molecular remission after AIDA induction and consolidation. Furthermore, we report the outcome of patients with molecularly persistent disease treated with salvage therapy.Patients attaining molecular remission (n=650) and patients who tested PCR+ve at the end of consolidation (n=23) were not statistically significantly different as regards median age, white cell and platelet counts, morphologic subtype (M3 or M3v), fibrinogen levels or PML/RARalpha transcript type. As to treatment outcome after salvage therapy, 7 patients were treated before morphologic relapse [3 with chemotherapy and autologous stem cell transplantation (SCT) and 4 with allogeneic SCT], and are alive after 64-118 months. Of 16 patients treated at the time of morphologic relapse, only 2 patients are alive, both of whom received an allogeneic SCT.Our findings indicate that APL patients who are molecularly resistant to the AIDA protocol have no distinguishing features at presentation. Their outcome suggests the need for early therapeutic intervention with aggressive treatment prior to the occurrence of hematologic relapse.

Published
2004

36. The Italian Way of Treating Acute Promyelocytic Leukemia (APL), Final Act

Author

Avvisati, G., Petti, M. C., LO COCO, F., Testi, A. M., Fazi, P., Specchia, G., Malagola, M., DI BONA, E., Recchia, A., Marmont, F., Buelli, M., Lazzarino, M., DI RAIMONDO, Francesco, Leoni, F., Kropp, M. G., Veneri, D., Micolis, I., Rossi, G., Venditti, A., and Mandelli, F.

Published
2003

39. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis

Author

Busca, A, Cavecchia, I, Locatelli, Franco, D'Ardia, S, De Rosa, F G, Marmont, F, Ciccone, G, Baldi, I, Serra, R, Gaido, E, Falda, M, Locatelli, F (ORCID:0000-0002-7976-3654), Busca, A, Cavecchia, I, Locatelli, Franco, D'Ardia, S, De Rosa, F G, Marmont, F, Ciccone, G, Baldi, I, Serra, R, Gaido, E, Falda, M, and Locatelli, F (ORCID:0000-0002-7976-3654)

Abstract

Blood stream infections (BSIs) remain one of the major causes of morbidity and mortality for patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). In the present study, we evaluated the incidence and characteristics of BSIwithin 1year after allogeneic HSCT in 269 consecutive adult patients who received antibacterial prophylaxis with levofloxacin. Cumulative incidence of BSI was 12%(95% confidence interval, 8 16%). Bacteria were responsible for 30 out of the 32 BSIs, while fungi were responsible for 2 episodes of BSI. The median onset of BSI was day 8 (range 1 328 days) post transplant, and 66% of BS occurred before neutrophil recovery. Gram-positive organisms accounted for 60%(n = 518) of bacteremia, and gram-negative isolates for 40%(n = 512) of the cases. Coagulasenegative staphylococci were the most commonly isolated gram-positive pathogens (53% of the cases), while Escherichia coli was the most commonly isolated gram-negative bacteria (58% of the cases). Candida albicans and Candida guillermondii were isolated from patients with candidemia. Resistance to uoroquinolones (FQ) was common with 13% of gram-positive isolates being susceptible to FQ, while 50% of the gram-negative rods were susceptible to FQ. Crude mortality and mortality attributable to BSI were both 3%(1 of 32). In conclusion, our data suggest that despite the emergence of antibiotic resistance, FQ prophylaxis may be considered an appealing approach in allogeneic HSCT recipients and is also worth evaluating in randomized studies.

Published
2012

43. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy

Author

Boccadoro, Mario, Tarella, C, Palumbo, A, Argentino, C, Triolo, S, Dominietto, A, Callea, V, Lauta, Vm, Molica, S, Musto, P, Marmont, F, Gianni, Am, and Pileri, A.

Subjects
Dose-Response Relationship, Drug, Plasma Cells, Antineoplastic Agents, Cell Count, Middle Aged, Severity of Illness Index, Disease-Free Survival, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Humans, Longitudinal Studies, Multiple Myeloma, beta 2-Microglobulin, Follow-Up Studies
Abstract

The clinical advantage of high-dose therapy (HDT) over standard treatment for multiple myeloma (MM) patients has been recently assessed. Which patient subgroups benefit most from this approach is unclear.To address this issue, the outcome of 54 patients under 55 years old treated with HDT was compared with that of 101 age-matched controls selected from 390 patients who received standard melphalan and prednisone (MP) chemotherapy in a national multi-center trial (M90 protocol).The complete response (CR) rate was 50% in the HDT group compared to 5% in the MP group. Event-free survival (EFS) was three times longer for the HDT patients (median 34.5 vs 12.2 months, p0. 0001), though the controls enjoyed a prolonged survival after relapse, and hence there was no statistically significant difference in OS. Overall survival (OS) was analyzed in relation to to two major prognostic factors: b(2)-microglobulin (b(2)-M) and bone marrow plasma cell labeling index (LI). HDT significantly improved OS in poor prognosis patients with a high LI (1.2%), (median 49.5 vs 32.5 months, p0.03), whereas it did not prolong OS in poor prognosis patients with high b(2 )-M (3 mg/L).In conclusion, HDT has a major impact on CR and EFS, and is the treatment of choice for patients with a high LI. Alternative strategies should be adopted in poor prognosis patients with high b(2 )-M.

Published
1999

44. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

Author

Mandelli, F., Vignetti, M., Suciu, S., Stasi, R., Petti, M.C., Meloni, G., Muus, P., Marmont, F., Marie, J.P., Labar, B., Thomas, X., Raimondo, F. Di, Willemze, R., Liso, V., Ferrara, F., Baila, L., Fazi, P., Zittoun, R., Amadori, S., Witte, T.J.M. de, Mandelli, F., Vignetti, M., Suciu, S., Stasi, R., Petti, M.C., Meloni, G., Muus, P., Marmont, F., Marie, J.P., Labar, B., Thomas, X., Raimondo, F. Di, Willemze, R., Liso, V., Ferrara, F., Baila, L., Fazi, P., Zittoun, R., Amadori, S., and Witte, T.J.M. de

Abstract

Contains fulltext : 79924.pdf (publisher's version ) (Closed access), PURPOSE: To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML). PATIENTS AND METHODS: We randomly assigned 2,157 patients (age range, 15 to 60 years) to receive intensive induction-consolidation chemotherapy containing either daunorubicin, idarubicin, or mitoxantrone. After achieving complete remission (CR), patients were assigned to undergo either allogeneic or autologous stem-cell transplantation (SCT), depending on the availability of a sibling donor. RESULTS: The overall CR rate (69%) was similar in the three groups. Autologous SCT was performed in 37% of cases in the daunorubicin arm versus only 29% and 31% in mitoxantrone and idarubicin, respectively (P < .001). However, the disease-free survival (DFS) and survival from CR were significantly shorter in the daunorubicin arm: the 5-year DFS was 29% versus 37% and 37% in mitoxantrone and idarubicin, respectively. The proportion of patients who underwent allogeneic SCT (22%) was equivalent in the three treatment groups, and the outcome was similar as well: the 5-year overall survival rates were 34%, 34%, and 31%, respectively. CONCLUSION: In adult patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy.

Published
2009

49. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience

Author

Pulsoni, A., primary, Iacobelli, S., additional, Bernardi, M., additional, Borgia, M., additional, Camera, A., additional, Cantore, N., additional, Di Raimondo, F., additional, Fazi, P., additional, Ferrara, F., additional, Leoni, F., additional, Liso, V., additional, Mancini, M., additional, Marmont, F., additional, Matturro, A., additional, Maurillo, L., additional, Melillo, L., additional, Meloni, G., additional, Mirto, S., additional, Specchia, G., additional, Valentini, C. G., additional, Venditti, A., additional, Leone, G., additional, Foa, R., additional, Mandelli, F., additional, and Pagano, L., additional

Published
2008
Full Text
View/download PDF

50. P002 Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register

Author

Gioia, D., primary, Cilloni, D., additional, Salvi, F., additional, Audisio, E., additional, Boccomini, C., additional, Bonferroni, M., additional, Cametti, G., additional, Ciravegna, G., additional, Darbesio, A., additional, Dellacasa, C., additional, Ferrero, D., additional, Freilone, R., additional, Gatto, S., additional, Lunghi, M., additional, Gallamini, A., additional, Gaidano, G., additional, Girotto, M., additional, Marmont, F., additional, Marinone, C., additional, Messa, E., additional, Perticone, S., additional, Pollio, B., additional, Tonso, A., additional, Saglio, G., additional, and Levis, A., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results